Want to see CH:GALD full AI Analyst Report?
GALD Stock Chart & Stats
CHF156.85
-CHF8.02(-7.15%)
At close: 4:00 PM EST
CHF156.85
-CHF8.02(-7.15%)
Day’s Range― - ―
52-Week RangeCHF122.70 - CHF188.25
Previous CloseN/A
Volume230.69K
Average Volume (3M)337.59K
Market Cap
CHF39.63B
Enterprise ValueCHF52.72B
Total Cash (Recent Filing)CHF780.00M
Total Debt (Recent Filing)CHF2.75B
Price to Earnings (P/E)77.0
Beta0.80
Next Earnings
Jul 23, 2026EPS Estimate
1.43Next Dividend Ex-DateN/A
Dividend Yield0.09%
Share Statistics
EPS (TTM)2.69
Shares Outstanding237,897,630
10 Day Avg. Volume210,266
30 Day Avg. Volume337,589
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)5.94
Price to Sales (P/S)9.24
P/FCF Ratio46.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF194.00Price Target Upside23.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)4.63
Revenue Forecast (FY)CHF6.32B
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Operating LeverageSustained gross margins near 67–70% and rising operating leverage indicate durable profitability from product mix and scale. This margin profile supports reinvestment in R&D and marketing, cushions pricing pressure in elective markets, and underpins long-term cash conversion.
Materially Reduced LeverageA sharp decline in debt-to-equity to ~0.34–0.35x reflects meaningful balance-sheet repair and greater financial flexibility. Lower leverage reduces refinancing risk, supports investment or M&A optionality, and improves resilience to cyclical dips in elective demand.
Strong Cash Generation In 2025Robust 2025 operating cash flow (~1.19B) and FCF (~1.03B) show improved cash conversion and capacity to fund dividends, deleveraging, or product investments. Consistent cash generation strengthens strategic options and reduces reliance on external financing.
Bears Say
Uneven Top-line GrowthA revenue decline in 2025 versus 2024 while profitability improved suggests earnings gains were driven by cost or mix shifts rather than sustainable volume growth. Persistent uneven top-line trends could limit long-term margin sustainability and constrain organic expansion.
Large Absolute Debt StockDespite improved leverage ratios, an absolute debt load near $2.75B remains material. If growth weakens or interest costs rise, servicing that debt could pressure free cash flow and limit capital allocation to R&D, marketing, or M&A over the medium term.
Historic Cash-flow VolatilityPrior years showed weak or negative FCF and volatile operating cash, indicating earlier fragility in cash quality. This history raises risk that current strong cash performance may revert in downturns, challenging sustained investment and shareholder returns.
Galderma Group AG News
GALD FAQ
What was Galderma Group AG’s price range in the past 12 months?
Galderma Group AG lowest stock price was CHF122.70 and its highest was CHF188.25 in the past 12 months.
What is Galderma Group AG’s market cap?
Galderma Group AG’s market cap is CHF39.63B.
When is Galderma Group AG’s upcoming earnings report date?
Galderma Group AG’s upcoming earnings report date is Jul 23, 2026 which is in 6 days.
How were Galderma Group AG’s earnings last quarter?
Galderma Group AG released its earnings results on Mar 05, 2026. The company reported CHF1.64 earnings per share for the quarter, beating the consensus estimate of CHF1.273 by CHF0.367.
Is Galderma Group AG overvalued?
According to Wall Street analysts Galderma Group AG’s price is currently Undervalued.
Does Galderma Group AG pay dividends?
Galderma Group AG pays a Notavailable dividend of CHF0.35 which represents an annual dividend yield of 0.09%. See more information on Galderma Group AG dividends here
What is Galderma Group AG’s EPS estimate?
Galderma Group AG’s EPS estimate is 1.43.
How many shares outstanding does Galderma Group AG have?
Galderma Group AG has 237,897,630 shares outstanding.
What happened to Galderma Group AG’s price movement after its last earnings report?
Galderma Group AG reported an EPS of CHF1.64 in its last earnings report, beating expectations of CHF1.273. Following the earnings report the stock price went up 6.975%.
Which hedge fund is a major shareholder of Galderma Group AG?
Currently, no hedge funds are holding shares in CH:GALD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
GALD Stock 12 Month Forecast
Average Price Target
CHF194.00
▲(23.69% Upside)